Diane F Jelinek, PhD

Professor, Rochester, MN, Immunology

Emailjelinek.diane@mayo.edu

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Diane F Jelinek is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

1 Active
8 Finished

MOLECULAR CLONING OF BILE ACID BIOSYNTHESIS GENES
Jelinek, D. F. & Jelinek, D. F.
National Institute of General Medical Sciences, National Institutes of Health
2/28/89 → …
Project: Research project
Role of lncRNAs in Clinical Heterogeneity of Early Stage IGHV Unmutated CLL
Jelinek, D. F.
National Cancer Institute
9/1/15 → 8/31/17
Project: Research project
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease Progression
Jelinek, D. F.
National Cancer Institute
7/1/15 → 6/30/20
Project: Research project
Metabolic Reprogramming: Essential Role and Early Marker of MGUS Progression
Jelinek, D. F., Kinney, L. & Kinney, L.
National Cancer Institute
8/1/12 → 7/31/14
Project: Research project
CD147 Biological Function and Role as a Biomarker of MGUS to Myeloma Progression
Jelinek, D. F. & Kinney, L.
National Cancer Institute
3/1/12 → 2/28/14
Project: Research project

11487 Citations
65 Scopus h-Index
175 Article
12 Letter
7 Comment/debate
4 Chapter
More
- 3 Review article

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
ERIC, the European Research Initiative on CLL, Mar 11 2021, In: Blood. 137, 10, p. 1365-1376 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
2 Scopus citations
A rare case of selective Igκ chain deficiency: Biologic and clinical implications
Sadighi Akha, A. A., Tschumper, R. C., Mills, J. R., Isham, C. R., Witty, E. E., Viswanatha, D. S., Dasari, S., Snyder, M. R., Murray, D. L., Katzmann, J. A., Jelinek, D. F. & Willrich, M. A. V., Nov 2020, In: Journal of Allergy and Clinical Immunology. 146, 5, p. 1208-1210.e6
Research output: Contribution to journal › Article › peer-review

Open Access
Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture
Walters, D. K. & Jelinek, D. F., Feb 1 2020, In: Journal of Histochemistry and Cytochemistry. 68, 2, p. 99-112 14 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial
Shanafelt, T. D., Wang, V., Kay, N. E., Hanson, C. A., O'Brien, S. M., Barrientos, J. C., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A., Mullane, M. P., Little, R. F., Erba, H. P., Stone, R. M., Litzow, M. & 1 others, Tallman, M. S., Nov 13 2019, In: Blood. 134, 1, p. 33 1 p.
Research output: Contribution to journal › Article › peer-review
11 Scopus citations
Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S. E., Barr, P. M., Cashen, A. F., Mato, A. R., Singh, A. K., Mullane, M. P., Little, R. F., Erba, H., Stone, R. M., Litzow, M. & 1 others, Tallman, M., Aug 1 2019, In: New England Journal of Medicine. 381, 5, p. 432-443 12 p.
Research output: Contribution to journal › Article › peer-review
152 Scopus citations